» Articles » PMID: 11815469

Is Reduced First-phase Insulin Release the Earliest Detectable Abnormality in Individuals Destined to Develop Type 2 Diabetes?

Overview
Journal Diabetes
Specialty Endocrinology
Date 2002 Jan 30
PMID 11815469
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin is released from the pancreas in a biphasic manner in response to a square-wave increase in arterial glucose concentration. The first phase consists of a brief spike lasting approximately 10 min followed by the second phase, which reaches a plateau at 2-3 h. It is widely thought that diminution of first-phase insulin release is the earliest detectable defect of beta-cell function in individuals destined to develop type 2 diabetes and that this defect largely represents beta-cell exhaustion after years of compensation for antecedent insulin resistance. In this article, the origins of these concepts are reviewed and recent evidence is presented suggesting that reductions in both phases of insulin release are equally early, that they precede insulin resistance other than that simply due to obesity, and that they therefore may represent the primary genetic risk factor predisposing individuals to type 2 diabetes.

Citing Articles

Biphasic glucose-stimulated insulin secretion over decades: a journey from measurements and modeling to mechanistic insights.

Peng X, Wang K, Chen L Life Metab. 2025; 4(1):loae038.

PMID: 39872989 PMC: 11770817. DOI: 10.1093/lifemeta/loae038.


Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review.

Herascu A, Avram V, Gaita L, Alexandra S, Reurean-Pintilei D, Timar B Medicina (Kaunas). 2025; 60(12.

PMID: 39768947 PMC: 11678706. DOI: 10.3390/medicina60122067.


Online Direct Infusion Mass Spectrometry of Liquid-Liquid Extraction Phases for Metabolite and Lipid Profiling with the Direct Infusion Probe.

Marques C, Blaase L, Lanekoff I Metabolites. 2024; 14(11).

PMID: 39590823 PMC: 11596504. DOI: 10.3390/metabo14110587.


Detection and Intervention: Use of Continuous Glucose Monitoring in the Early Stages of Type 2 Diabetes.

Miller E, Miller K Clin Diabetes. 2024; 42(3):398-407.

PMID: 39015167 PMC: 11247044. DOI: 10.2337/cd23-0077.


Surrogate measures of first-phase insulin secretion versus reference methods intravenous glucose tolerance test and hyperglycemic clamp: a systematic review and meta-analyses.

Renklint R, Chninou Y, Heni M, Fritsche A, Haering H, Wagner R BMJ Open Diabetes Res Care. 2024; 12(4).

PMID: 39013634 PMC: 11268049. DOI: 10.1136/bmjdrc-2024-004256.